Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefazolin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.98 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.98 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.98 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.98 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 9/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.84 |
| ▸ | BLM | P54132 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.84 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.84 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | PDE4A | P27815 | 1/20 | 0.72 |
| ▸ | KDR | P35968 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 9/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefazolin SCHEMBL11031717 | 0.99 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL4930576 | 0.99 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL2841 | 0.99 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL3424683 | 0.99 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL2842 | 0.99 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL16072809 | 0.99 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL3894722 | 0.99 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL40736 | 0.98 | LMNA (0.98) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL6364010 | 0.98 | LMNA (0.98) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL29204288 | 0.98 | LMNA (0.98) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000644-A1 | Biocompatible Biodegradable Intraocular Implant System | INSIGHT INNOVATIONS, LLC (US) | 2017-01-05 | — | — | US | claimed |
| US-20110230963-A1 | BIOCOMPATIBLE BIODEGRADABLE INTRAOCULAR IMPLANT SYSTEM | INSIGHT INNOVATIONS, LLC | 2011-09-22 | — | — | US | claimed |
| EP-2364127-A2 | BIOCOMPATIBLE BIODEGRADABLE INTRAOCULAR IMPLANT SYSTEM | Insight Innovations, Llc (US) | 2011-09-14 | — | — | EP | claimed |
| WO-2010059214-A2 | BIOCOMPATIBLE BIODEGRADABLE INTRAOCULAR IMPLANT SYSTEM | INSIGHT INNOVATIONS, LLC (US) | 2010-05-27 | — | — | WO | claimed |
| US-20240226022-A1 | TIME RELEASED BIODEGRADABLE OR BIOERODIBLE MICROSPHERES OR MICROPARTICLES SUSPENDED IN A SOLIDIFYING DEPOT-FORMING INJECTABLE DRUG FORMULATION | ALLERGAN, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-115335050-B | Compounds and compositions for treating skin disorders | 卡玛瑞制药有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-11975049-B2 | Therapeutic treatment for neurotrophic keratopathy | Struck, Michael (US) | 2024-05-07 | — | — | US | disclosed |
| CN-117580560-A | Micronised lipid | MCAL治疗公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230390212-A1 | TIME RELEASED BIODEGRADABLE OR BIOERODIBLE MICROSPHERES OR MICROPARTICLES SUSPENDED IN A SOLIDIFYING DEPOT-FORMING INJECTABLE DRUG FORMULATION | ALLERGAN, INC. | 2023-12-07 | — | — | US | disclosed |
| US-20230165885-A1 | TREATMENT OF EYE DISORDERS WITH URIDINE PHOSPHATE DERIVATIVES | GLIAGUARD, INC. | 2023-06-01 | — | — | US | disclosed |
| CN-114728093-B | Wound dressing for hemostasis and wound healing and preparation method thereof | 株式会社MEDITIP | 2023-04-28 | — | — | CN | disclosed |
| US-11622951-B2 | Alpha-aminoadipate for treatment of vision loss and restoring sight | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20050244467-A1 | Implanting the extended release, biodegradable implant containing dexamethasone directly into the vitreous of the eye; side effect reduction; angiogenesis inhibition; macular degeneration | ALLERGAN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| US-20050244469-A1 | Inserting an implant into an ocular site; an active agent and a polymer carrier; releasing the active agent from the implant | ALLERGAN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| US-20050244462-A1 | Devices and methods for treating a mammalian eye | ALLERGAN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| US-20050191334-A1 | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents | ALLERGAN, INC. (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050048098-A1 | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents | ALLERGAN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| US-20030095995-A1 | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents | ALLERGAN, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6369116-B1 | SUSTAINED RELEASE DEXAMETHASON | OCULEX PHARMACEUTICALS, INC. | 2002-04-09 | — | — | US | disclosed |
| US-5869079-A | SEMIRIGID IMPLANT OF GLYCOLIC ACID-LACTIC ACID COPOLYMER WITH HYDROPHILIC HYDROXYPROPYLMETHYLCELLULOSE AS A RELEASE MODIFIER FOR THE HYDROPHOBIC DRUG DEXAMETHASONE; CONSTANT RELEASE RATE, NO ?DUMPING? | OCULEX PHARMACEUTICALS, INC. (US) | 1999-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11622951-B2 | Alpha-aminoadipate for treatment of vision loss and restoring sight | AADAT, PDE6A, PDE6C | LMNA 1669/4885PTGS2 641/4885SLC22A6 3206/4885 |
| US-20240226022-A1 | TIME RELEASED BIODEGRADABLE OR BIOERODIBLE MICROSPHERES OR MICROPARTICLES SUSPENDED IN A SOLIDIFYING DEPOT-FORMING INJECTABLE DRUG FORMULATION | VEGFA, NEFM, PDE6D | LMNA 2535/4885PTGS2 1216/4885SLC22A6 1680/4885 |
| US-20230390212-A1 | TIME RELEASED BIODEGRADABLE OR BIOERODIBLE MICROSPHERES OR MICROPARTICLES SUSPENDED IN A SOLIDIFYING DEPOT-FORMING INJECTABLE DRUG FORMULATION | VEGFA, NEFM, PDE6D | LMNA 2535/4885PTGS2 1216/4885SLC22A6 1680/4885 |
| US-20230165885-A1 | TREATMENT OF EYE DISORDERS WITH URIDINE PHOSPHATE DERIVATIVES | P2RY6, P2RY1, P2RY2 | LMNA 3469/4885PTGS2 459/4885SLC22A6 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.